Oakworth Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Oakworth Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-413	Closed	-$3.11K	–	639
2023 Q2	$3.11K	Hold	413	–	–	﹤0.01%	571
2023 Q1	$3.65K	Hold	413	–	–	﹤0.01%	520
2022 Q4	$3.77K	Hold	413	–	–	﹤0.01%	500
2022 Q3	$3K	Hold	413	–	–	﹤0.01%	525
2022 Q2	$3K	Hold	413	–	–	﹤0.01%	516
2022 Q1	$4K	Hold	413	–	–	﹤0.01%	508
2021 Q4	$3K	Hold	413	–	–	﹤0.01%	553
2021 Q3	$4K	Sell	413 -106	-20%	-$993	﹤0.01%	528
2021 Q2	$5K	Hold	519	–	–	﹤0.01%	518
2021 Q1	$6K	Hold	519	–	–	﹤0.01%	497
2020 Q4	$5K	Hold	519	–	–	﹤0.01%	497
2020 Q3	$4K	Hold	519	–	–	﹤0.01%	510
2020 Q2	$6K	Hold	519	–	–	﹤0.01%	459
2020 Q1	$4K	Hold	519	–	–	﹤0.01%	451
2019 Q4	$4K	Hold	519	–	–	﹤0.01%	491
2019 Q3	$3K	Sell	519 -3,200	-86%	-$24.5K	﹤0.01%	520
2019 Q2	$35K	Hold	3,719	–	–	0.01%	363
2019 Q1	$58K	Buy	3,719 +413	+12%	+$7.28K	0.01%	287
2018 Q4	$51K	Hold	3,306	–	–	0.01%	286
2018 Q3	$71K	Hold	3,306	–	–	0.01%	267
2018 Q2	$80K	Buy	3,306 +3,200	+3,019%	+$65.3K	0.02%	245
2018 Q1	$2K	Hold	106	–	–	﹤0.01%	572
2017 Q4	$2K	Hold	106	–	–	﹤0.01%	577
2017 Q3	$2K	Hold	106	–	–	﹤0.01%	592
2017 Q2	$4K	Hold	106	–	–	﹤0.01%	544
2017 Q1	$3K	Hold	106	–	–	﹤0.01%	562
2016 Q4	$4K	Buy	+106	New	+$4.23K	﹤0.01%	551

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Oakworth Capital's TEVA Position: Q3 2023 in Review

Oakworth Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 413 shares — an estimated $3.11K sold.

Oakworth Capital first reported a position in TEVA in Q4 2016 and held it in 27 quarters. The position peaked at $80K in Q2 2018. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Oakworth Capital reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Oakworth Capital sold 413 Teva Pharmaceuticals shares in Q3 2023, an estimated $3.11K.
Oakworth Capital first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 27 quarters.
Oakworth Capital's Teva Pharmaceuticals position peaked at $80K in Q2 2018.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Oakworth Capital's 13F filing for Q3 2023, filed 31 Oct 2023.